Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia parte 2: Tratamento de longo prazo

Translated title of the contribution: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 2: Long-term treatment

Peter Falkai, Thomas Wobrock*, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Hans Jürgen Möller, A. Carlo Altamura, Nancy Andreasen, Thomas R E Barnes, Helmut Beckmann, Jorge Ciprian-Ollivier, Tim Crow, Anthony David, Michael Davidson, Bill Deakin, Helio Elkis, Lars Farde, Wolfgang Gaebel, Bernd Gallhofer, Jes GerlachSteven Richard Hirsch, Carlos R. Hojaij, Assen Jablensky, John Kane, Takuja Kojima, Lars Von Knorring, Patrick McGorry, Herbert Meltzer, Driss Moussaoui, Franz Müller-Spahn, Jean Pierre Olie, A. Pacheco Palha, Mitsumoto Sato, Heinrich Sauer, Nina Schooler, Daniel Weinberger, Shigeto Yamawaki

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Scopus citations


These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A/D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.

Original languagePortuguese
Pages (from-to)65-100
Number of pages36
JournalRevista de Psiquiatria Clinica
Issue numberSUPPL. 1
StatePublished - Dec 1 2006



  • Antipsychotics
  • Biological treatment
  • Evidence-based medicine
  • Long-term treatment
  • Practice guidelines
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H. J., Altamura, A. C., Andreasen, N., Barnes, T. R. E., Beckmann, H., Ciprian-Ollivier, J., Crow, T., David, A., Davidson, M., Deakin, B., Elkis, H., Farde, L., Gaebel, W., Gallhofer, B., ... Yamawaki, S. (2006). Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia parte 2: Tratamento de longo prazo. Revista de Psiquiatria Clinica, 33(SUPPL. 1), 65-100.